Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported Licence

Diastereoselective synthesis of cyclopropyl sulfoxides via hydrosulfenation

Liyan Yuwen , Jiazhong Tang, Yayu Qi, Tianyi Zou, Shaotong Zhang, Ya-Qian Zhang and Qing-Wei Zhang*
Key Laboratory of Precision and Intelligent Chemistry, Department of Chemistry, University of Science and Technology of China, Hefei 230026, China. E-mail: qingweiz@ustc.edu.cn

Received 10th November 2025 , Accepted 12th December 2025

First published on 12th December 2025


Abstract

Cyclopropyl sulfoxides, merging two privileged motifs in medicinal chemistry, remain synthetically challenging despite their pharmaceutical potential. Herein, we report a mild, metal-free hydrosulfenation strategy that enables their direct synthesis, achieving exceptional diastereoselectivity (dr up to > 20[thin space (1/6-em)]:[thin space (1/6-em)]1) in systems with up to eight possible diastereomers. Chiral sulfoxides with 4 to 7 stereogenic centers were also synthesized in high dr. The methodology provides direct access to medicinally relevant architectures, including cyclopropyl sulfones, sulfoximines, and drug-conjugated hybrids. Mechanistic studies reveal stereochemical control via collective spatial factors including endo/exo, facial and side selectivities during the cycloaddition step.


Introduction

Cyclopropane and sulfoxide moieties represent two privileged structural motifs in modern drug discovery, each endowing molecules with distinct physicochemical and pharmacological properties.1–9 Systematic analyses of pharmaceutical compounds underscore their clinical significance: cyclopropane ranks as the 10th most prevalent ring system in marketed drugs,10 while sulfur-containing structures appear in nearly 300 FDA-approved small-molecule therapeutics. Within this sulfur pharmacophore landscape, approximately 4% of these drugs incorporate the sulfoxide functional group.11

Given the significant individual contributions of cyclopropane and sulfoxide moieties to medicinal chemistry, exploring the potential of their combined structure, cyclopropyl sulfoxides, is highly compelling. This integration is anticipated to synergize the cyclopropane ring's rigid geometry and metabolic stability with the sulfoxide's ambident polarity and bioisosteric versatility, thereby rendering novel therapeutic profiles. Beyond their intrinsic value as potential bioactive entities, cyclopropyl sulfoxides serve as pivotal synthetic intermediates for accessing other sulfur-containing cyclopropane architectures. For instance, they can be oxidized to cyclopropyl sulfones or converted to cyclopropyl sulfoximines12–17—structural motifs present in clinically approved drugs18 (Fig. 1a).


image file: d5sc08731g-f1.tif
Fig. 1 Construction of cyclopropyl sulfoxides, applications and challenges.

Despite this promising potential, the development of robust synthetic methods for cyclopropyl sulfoxides remains scarce. Among the limited potential approaches, sulfenic acid-mediated pathways represent a promising yet challenging route.19–21 Sulfenic acids are highly transient species, prone to facile dimerization or disproportionation22–25 (Fig. 1b). Their nucleophilic addition across unsaturated systems has been mainly documented with relatively electrophilic alkynes, while the corresponding reaction with alkenes remains virtually unexplored.26–29 We thus envisioned extending this unconventional reaction mode to cyclopropenes.

However, the engagement of the electrically neutral, yet highly strained, cyclopropene π-system introduces distinct challenges.30 The inherent ring strain, while a potential driver of reactivity, predisposes the system to ring-opening side reactions.31–37 Furthermore, the simultaneous construction of multiple stereocenters in the product renders stereocontrol—particularly in non-metal-catalyzed systems—a formidable task (Fig. 1b). Conventional non-transition-metal-catalyzed mechanisms often involve stepwise ionic additions to the cyclopropene double bond, generating cyclopropyl cation or anion intermediates that subsequently react with nucleophiles or electrophiles.38,39

Herein, we report the hydrosulfenation of cyclopropenes to diastereoselectively synthesize cyclopropyl sulfoxides (Fig. 1c). In contrast to previous stepwise ionic pathways, the reaction proceeds through concerted cycloaddition between sulfenic acid intermediates and cyclopropenes. Moreover, excellent diastereoselectivity (dr up to > 20[thin space (1/6-em)]:[thin space (1/6-em)]1) over a potential pool of up to eight diastereomers was successfully achieved, governed by a well-defined hierarchy of spatial control elements during the cycloaddition transition state.

Results and discussion

To validate the proposed reaction pathway, we commenced our study by conducting the reaction with sulfoxide 1a (as the sulfenic acid precursor) and cyclopropene 2m as model substrates for initial optimization studies (see SI Table S1 online).

The extensive screening of reaction parameters revealed two critical determinants of reaction efficiency and selectivity. First, evaluation of bases demonstrated a significant influence on reaction efficiency, with weakly basic additives affording superior yields compared to strong bases. We hypothesize that gradual sulfenic acid release under mild basic conditions minimizes undesired side reactions, allowing efficient cyclopropene engagement. Second, steric differentiation between cyclopropene substituents emerged as the dominant factor governing diastereoselectivity. Introducing pronounced steric contrast dramatically enhanced stereocontrol. As a consequence, the optimal condition was identified as treating the sulfoxide and cyclopropene substrates with 1 equiv 4-methylmorpholine (NMM) in toluene (0.1 M) at 60 °C.

With the optimized reaction conditions established, we next explored the substrate scope of this reaction (Table 1). Initially, cyclopropene substrates bearing diverse substituents were investigated. A number of alkyl and aryl variants (3a–3f) delivered corresponding products in high yields (70–85%) with exceptional stereocontrol (dr > 20[thin space (1/6-em)]:[thin space (1/6-em)]1) over four pairs of possible diastereomers. In particular, the ferrocenyl group was proved compatible, with 3g furnished in retained diastereoselectivity (dr > 20[thin space (1/6-em)]:[thin space (1/6-em)]1) albeit in moderated yield. Substrates with less hindered aromatic groups (e.g., phenyl, naphthyl) afforded 3h–3n in excellent yields (72–94%), though with attenuated stereoselectivity (dr 4[thin space (1/6-em)]:[thin space (1/6-em)]1 to 5[thin space (1/6-em)]:[thin space (1/6-em)]1).

Table 1 Substrate scope of cyclopropenes and racemic sulfoxides. Reaction conditions: 0.1 mmol sulfoxide, 0.11 mmol cyclopropene, 0.1 mmol NMM, 1 mL toluene and at 60 °C; 0.1 mmol scale with isolated yields; dr determined by molar ratio of isolated products
image file: d5sc08731g-u1.tif


To further demonstrate the versatility of this protocol, a broad scope of sulfenic acid precursors were examined. Sulfoxides bearing both weak electron-donating groups (3p–3s) and electron-withdrawing substituents (3t–3x) generated products efficiently (65–81% yield) without compromising diastereoselectivity (dr > 20[thin space (1/6-em)]:[thin space (1/6-em)]1), highlighting the reaction's tolerance to electronic perturbations. Alkyl sulfoxides also participated effectively, yielding 3y–3ab with high efficiency (63–71% yield) and robust stereocontrol (dr 16[thin space (1/6-em)]:[thin space (1/6-em)]1 to >20[thin space (1/6-em)]:[thin space (1/6-em)]1). Collectively, these results establish a broad substrate compatibility as well as excellent diastereoselectivity spanning diverse cyclopropenes and sulfoxides. In particular, product 3ac contains the same cyclopropyl amide structural fragment found in anti-depressant milnacipran.

Building upon the diastereoselective hydrosulfenation methodology, we next pursued the integration of sulfur-centered chirality40–46 into this framework using enantioenriched sulfenic acid precursors and chiral cyclopropenes (Table 2). Combined with the strain-release desymmetrization strategy, a series of sulfur-stereogenic cyclopropyl sulfoxides (4a–4m) were synthesized with precise control over both the newly formed S-chirality and existing stereocenters. In particular, for substrates containing chiral benzylic groups, products (4a–4i) were obtained with complete retention of the original stereocenter configuration while simultaneously establishing three new stereogenic elements (S-center and two cyclopropane carbons), achieving exceptional diastereoselectivity (dr up to >20[thin space (1/6-em)]:[thin space (1/6-em)]1) among eight possible diastereomers.

Table 2 Substrate scope of chiral sulfoxides. Reaction conditions: 0.1 mmol sulfoxide, 0.11 mmol cyclopropene, 0.1 mmol NMM, 1 mL toluene and at 60 °C; 0.1 mmol scale with isolated yields; dr determined by molar ratio of isolated products
image file: d5sc08731g-u2.tif


Employing substrates with natural product fragments, including menthone derivatives (4j), dihydrocarvone derivatives (4k, 4k″, two diastereomers shown), natural borneol derivatives (4l), and fructose derivatives (4m), compounds containing up to 7 stereocenters were successfully obtained in moderate yields. The preserved stereochemical integrity at sensitive positions underscores the mildness and selectivity of the strain-release activation mode.

The synthetic utility of this methodology was further exemplified through diversified post-functionalizations (Fig. 2). Gram-scale synthesis of 3t (Fig. 2a) retained high efficiency (72% yield vs. 76% in small-scale) and stereoselectivity (dr > 20[thin space (1/6-em)]:[thin space (1/6-em)]1), confirming its excellent scalability for preparative applications. Subsequent methyl substitution at the sulfinyl-adjacent position was performed smoothly with moderate yields (Fig. 2b). Furthermore, sulfur-centric diversification was achieved by converting the sulfoxides into sulfoximines or sulfones, expanding accessible sulfur oxidation states and species. Oxidation to sulfone 5c (Fig. 2c) proceeded in 56% yield with preserved diastereoselectivity (dr > 20[thin space (1/6-em)]:[thin space (1/6-em)]1).47 For sulfoximines (Fig. 2d), the S[double bond, length as m-dash]N bond was constructed via copper-catalysed nitrene transfer,48,49 affording both 5d and S-stereogenic 5e in moderate yields (56% and 46%, respectively) with outstanding dr (>20[thin space (1/6-em)]:[thin space (1/6-em)]1). Finally, Pd-catalysed Suzuki cross-coupling with several drug molecules50 furnished drug-conjugated hybrids 5f–5i in high yields (70–99%) (Fig. 2e), demonstrating an easily accessible integration with complex pharmacophores. We believe these transformations have opened up a versatile platform for constructing stereochemically defined, functionally tunable cyclopropane architectures, with direct relevance to medicinal chemistry.


image file: d5sc08731g-f2.tif
Fig. 2 Derivatization of the cyclopropyl sulfoxide product.

To elucidate the mechanistic underpinnings of stereochemical control in this transformation, we conducted density functional theory (DFT) calculations on the model reaction yielding product 4a—a structure bearing four stereogenic elements (Fig. 3, 1*–4*). The configurationally fixed 1* center is inherited from the sulfoxide substrate 1o, while 2*–3* emerge through cyclopropene desymmetrization during cycloaddition with sulfenic acid intermediate Int-1. The sulfur stereocenter (4*) is dictated by the spatial geometry of this key bond-forming event. Collectively, these stereochemical determinants generate eight possible diastereomeric transition states (TS), corresponding to permutations of three variable stereochemical parameters beyond the fixed 1* center (for details of all eight transition states TS-2–TS-5, please see SI).


image file: d5sc08731g-f3.tif
Fig. 3 Computational studies. DFT calculated reaction pathways at M062X/def2-TZVP/SMD(Toluene)//B3LYP-D3/def2-SVP level. All energies are in kcal mol−1. (A): Overall energy profile. (B): Transition states regarding endo/exo and facial selectivity. (C): Side selectivity of carbon 2* vs. 2′*.

The reaction initiates with sulfoxide 1o generating sulfenic acid intermediate Int-1 through retro-Michael fragmentation, with an energy barrier of 26.1 kcal mol−1. Subsequently, Int-1 undergoes highly diastereoselective cycloaddition with benzannulated cyclopropene 2n engaging three distinct stereochemical modulation pathways. The dominant stereodifferentiation arises from the sulfur substituent's spatial orientation during cycloaddition. While the reaction proceeds through a coplanar five-membered transition state involving the S–O–H moiety and alkene π-system, the benzyl substituent adopts either endo (the benzyl substituent inward) or exo (the lone pair inward) configurations. Severe steric repulsion in endo-type TSs elevates their energy by 5.0 kcal mol−1 relative to exo-counterparts (TS-2-Rs vs. TS-2-Ss), establishing this as the primary stereochemical gatekeeper.

Beyond sulfur orientation, facial selectivity imposed by cyclopropene's rigid spiroindanyl group introduces secondary energy differentiation. Attack at the methylene face minimizes steric repulsion, whereas approach from the benzene face induces destabilizing repulsion originated from the C–H bond perpendicular to the π-system. A 2.7 kcal mol−1 energy gap was found between TS-2-Rs and TS-3-Rs, rationalizing the observed facial preference.

Intriguingly, open-chain analog 4i exhibit reversed facial selectivity, as confirmed by single-crystal X-ray analysis of 4i's two major diastereomers. This phenomenon may arise from the free rotation of the benzene ring that relieves allylic strain, thereby making the benzene face sterically less hindered than the cyclopentyl side. Consequently, the reaction preferentially occurs at the lower-energy benzene face. These results collectively demonstrate that facial selectivity is governed by substituent-induced steric profiles, with reactions favoring the sterically less encumbered face.

The residual stereochemical modulation stems from the side selectivity of enantiotopic cyclopropene carbons. While pseudo-enantiomeric pathways involving opposite cyclopropene carbons exhibit closely spaced energy profiles (ΔΔG = 1.2 kcal mol−1, TS-2-Rs vs. TS-4-Rs), the fixed 1* center breaks this symmetry through differential van der Waals interactions at the cyclopropane–sulfoxide interface, thus determined the side selectivity (2* vs. 2′*).

Single-crystal X-ray diffraction unambiguously confirmed the structure of major diastereomer 4a, which aligns with the lowest–energy transition state (methylene-face exo attack) predicted by DFT calculations. While computational models identified 4a″-Ss—the pseudo-enantiomer differing solely in enantiotopic carbon selectivity—as the most probable minor product, its experimental isolation proved infeasible due to the exceptionally high diastereomeric ratio (dr > 20[thin space (1/6-em)]:[thin space (1/6-em)]1). To circumvent this limitation, we analyzed the stereochemical outcome of substrate 4i. X-ray characterization of 4i's two predominant diastereomers revealed the pseudo-enantiomeric relationship expected for 4a (between 4a and 4a″-Ss), except for the benzene-face preference inherent to 4i's open-chain design (as rationalized in the facial selectivity analysis). This structural congruence validates our computational results, as both systems share identical stereochemical determinants despite divergent substitution patterns. The conserved configuration relationships across substrates demonstrate the generalizability of the stereocontrol model, particularly the dominance of sulfur orientation and facial selectivity.

Conclusions

In summary, we have developed a hydrosulfenation strategy for the synthesis of cyclopropyl sulfoxides using cyclopropenes, achieving excellent diastereoselectivity (dr up to > 20[thin space (1/6-em)]:[thin space (1/6-em)]1), high yields, and broad substrate scope under mild, metal-free conditions. The methodology provides direct access to structurally diverse cyclopropyl sulfoxides, which exhibit versatile post-functionalization potential, including oxidation to sulfones, conversion to sulfoximines, and integration with pharmacophores. Mechanistic studies revealed that the stereochemical outcome arises from a series of spatial control elements: dominant sulfur substituent orientation (exo vs. endo), followed by facial selectivity dictated by benzannulation-induced steric effects, and subtle side discrimination of enantiotopic carbons in substrates with fixed stereocenters. These factors collectively drive the preferential formation of low-energy transition states, with exo addition at the sterically less hindered face being energetically favored.

Data availability

All other data are available from the corresponding authors upon request.

CCDC 2450631, 2431747, 2451688, 2450394 and 2450395 contain the supplementary crystallographic data for this paper.51a–e

Supplementary information: optimization studies, experimental procedures, mechanistic studies, computational studies, NMR spectra and high-resolution mass spectrometry. See DOI: https://doi.org/10.1039/d5sc08731g.

Author contributions

Q.-W. Z. conceived the project and designed the experiments. L. Y. YW., Y. Y. Q. and S. T. Z. performed the experimental work. J. Z. T. conducted computational studies. T. Y. Z and L. Y. YW. wrote the manuscript.

Conflicts of interest

There is no conflict of interest to report.

Acknowledgements

This work was supported by NSFC (22471251, 22501268). The simulations and computational work were supported by the robotic AI-Scientist platform of Chinese Academy of Science and have been done on the Supercomputing Center of the University of Science and Technology of China. This work was partially carried out at the Instruments Center for Physical Science, University of Science and Technology of China.

Notes and references

  1. A. De Meijere, Angew. Chem., Int. Ed., 1979, 18, 809–826 Search PubMed.
  2. S. S. Uthumange, A. J. H. Liew, X. W. Chee and K. Y. Yeong, Bioorg. Med. Chem., 2024, 116, 117980 CrossRef CAS PubMed.
  3. A. Gagnon, M. Duplessis and L. Fader, Org. Prep. Proced. Int., 2010, 42, 1–69 Search PubMed.
  4. C. M. Marson, Chem. Soc. Rev., 2011, 40, 5514–5533 Search PubMed.
  5. I. A. Novakov, A. S. Babushkin, A. S. Yablokov, M. B. Nawrozkij, O. V. Vostrikova, D. S. Shejkin, A. S. Mkrtchyan and K. V. Balakin, Russ. Chem. Bull., 2018, 67, 395–418 CrossRef CAS.
  6. D. Y.-K. Chen, R. H. Pouwer and J.-A. Richard, Chem. Soc. Rev., 2012, 41, 4631–4642 RSC.
  7. U. Lücking, Org. Chem. Front., 2019, 6, 1319–1324 RSC.
  8. C. Zhao, K. P. Rakesh, L. Ravidar, W.-Y. Fang and H.-L. Qin, Eur. J. Med. Chem., 2019, 162, 679–734 CrossRef CAS PubMed.
  9. E. Wojaczyńska and J. Wojaczyński, Curr. Opin. Chem. Biol., 2023, 76, 102340–102348 CrossRef PubMed.
  10. R. D. Taylor, M. MacCoss and A. D. G. Lawson, J. Med. Chem., 2014, 57, 5845–5859 CrossRef CAS PubMed.
  11. K. A. Scott and J. T. Njardarson, Top. Curr. Chem., 2018, 376, 5 CrossRef.
  12. M. Frings, C. Bolm, A. Blum and C. Gnamm, Eur. J. Med. Chem., 2017, 126, 225–245 CrossRef CAS PubMed.
  13. T. Bach and C. Körber, Eur. J. Org Chem., 1999, 1999, 1033–1039 CrossRef.
  14. M. Zenzola, R. Doran, L. Degennaro, R. Luisi and J. A. Bull, Angew. Chem., Int. Ed., 2016, 55, 7203–7207 CrossRef CAS PubMed.
  15. H. Okamura and C. Bolm, Org. Lett., 2004, 6, 1305–1307 CrossRef CAS PubMed.
  16. T. Q. Davies, M. J. Tilby, J. Ren, N. A. Parker, D. Skolc, A. Hall, F. Duarte and M. C. Willis, J. Am. Chem. Soc., 2020, 142, 15445–15453 CrossRef CAS.
  17. X. Shen, Q. Liu, W. Zhang and J. Hu, Eur. J. Org Chem., 2016, 2016, 906–909 CrossRef CAS.
  18. Z. Časar, Synthesis, 2020, 52, 1315–1345 CrossRef.
  19. T. Z. Jia, M. N. Zhang, S. P. McCollom, A. Bellomo, S. Montel, J. Y. Mao, S. D. Dreher, C. J. Welch, E. L. Regalado, R. T. Williamson, B. C. Manor, N. C. Tomson and P. J. Walsh, J. Am. Chem. Soc., 2017, 139, 8337–8345 CrossRef CAS PubMed.
  20. F. Saito, Synthesis, 2024, 56, 220–228 CrossRef CAS.
  21. L. Gao, Y. Q. Wang, Y.-Q. Zhang, Y. H. Fu, Y. Y. Liu and Q.-W. Zhang, Angew. Chem., Int. Ed., 2024, 63, e202317626 CrossRef CAS.
  22. C. M. A. Gangemi, E. D'Agostino, M. C. Aversa, A. Barattucci and P. M. Bonaccorsi, Tetrahedron, 2023, 143, 133550 CrossRef CAS.
  23. S. E. Leonard, K. G. Reddie and K. S. Carroll, ACS Chem. Biol., 2009, 4, 783–799 CrossRef CAS.
  24. V. Gupta, J. Yang, D. C. Liebler and K. S. Carroll, J. Am. Chem. Soc., 2017, 139, 5588–5595 CrossRef CAS.
  25. S. L. Scinto, O. Ekanayake, U. Seneviratne, J. E. Pigga, S. J. Boyd, M. T. Taylor, J. Liu, C. W. Am Ende, S. Rozovsky and J. M. Fox, J. Am. Chem. Soc., 2019, 141, 10932–10937 CrossRef CAS.
  26. D. N. Neville Jones, P. D. Cottam and J. Davies, Tetrahedron Lett., 1979, 20, 4977–4980 CrossRef.
  27. A. V. Kalyanakrishnan, A. Joshy, A. K. Arya and A. Kaliyamoorthy, ChemistrySelect, 2021, 6, 14054–14059 CrossRef CAS.
  28. Y.-Q. Zhang, L. F. Hu, L. Y. Yuwen, G. Lu and Q.-W. Zhang, Nat. Catal., 2023, 6, 487–494 CrossRef CAS.
  29. L. J. Alcock, K. D. Farrell, M. T. Akol, G. H. Jones, M. M. Tierney, H. B. Kramer, T. L. Pukala, G. J. L. Bernardes, M. V. Perkins and J. M. Chalker, Tetrahedron, 2018, 74, 1220–1228 CrossRef CAS.
  30. R. Vicente, Chem. Rev., 2021, 121, 162–226 CrossRef CAS.
  31. A. K. Griffith, C. M. Vanos and T. H. Lambert, J. Am. Chem. Soc., 2012, 134, 18581–18584 CrossRef CAS.
  32. S. Ni, J. Chen and S. Ma, Org. Lett., 2013, 15, 3290–3293 CrossRef CAS.
  33. H. Fang, L. Yuwen, Y. Qi, J. Wang and Q.-W. Zhang, Synlett, 2025, 36, 1780–1784 CrossRef CAS.
  34. S. Nie, A. Lu, E. L. Kuker and V. M. Dong, J. Am. Chem. Soc., 2021, 143, 6176–6184 CrossRef CAS PubMed.
  35. S. Wang, X. Li, J. Song and X. Fang, Org. Chem. Front., 2025, 12, 3223–3229 RSC.
  36. A. Ali, C. Chung, J. Wang, L. Liu, Y. Kong, C. Wang, Y. Liu, Q. Yin and S. Lin, Org. Lett., 2025, 27, 740–746 CrossRef CAS PubMed.
  37. J. Han, Y. Liu, X. Yang, X. Zhang, Y. Zhu, M. Zhao, G. Hao and Y. Jiang, Org. Chem. Front., 2023, 10, 4887–4894 Search PubMed.
  38. J. García-Lacuna, G. Domínguez, Á. M. Martínez and J. Pérez-Castells, Org. Chem. Front., 2025, 12, 2525–2551 RSC.
  39. P. Li, X. Zhang and M. Shi, Chem. Commun., 2020, 56, 5457–5471 RSC.
  40. L. Wang, M. Chen, P. Zhang, W. Li and J. Zhang, J. Am. Chem. Soc., 2018, 140, 3467–3473 CrossRef CAS PubMed.
  41. M. J. Tilby, D. F. Dewez, A. Hall, C. Martínez Lamenca and M. C. Willis, Angew. Chem., Int. Ed., 2021, 60, 25680–25687 CrossRef CAS PubMed.
  42. X. Zhang, E. C. X. Ang, Z. Yang, C. W. Kee and C.-H. Tan, Nature, 2022, 604, 298–303 CrossRef CAS.
  43. S. Huang, Z. Zeng, N. Zhang, W. Qin, Y. Lan and H. Yan, Nat. Chem., 2023, 15, 185–193 CrossRef CAS.
  44. M. Liao, Y. Liu, H. Long, Q. Xiong, X. Lv, Z. Luo, X. Wu and Y. R. Chi, Chem, 2024, 10, 1541–1552 CAS.
  45. Z. Peng, S. Sun, M.-M. Zheng, Y. Li, X. Li, S. Li, X.-S. Xue, J. Dong and B. Gao, Nat. Chem., 2024, 16, 353–362 CrossRef CAS.
  46. T. Wei, H.-L. Wang, Y. Tian, M.-S. Xie and H.-M. Guo, Nat. Chem., 2024, 16, 1301–1311 CrossRef CAS PubMed.
  47. M. H. Ali and G. J. Bohnert, Synth. Commun., 1998, 28, 2983–2998 CrossRef CAS.
  48. P. Brandt, M. J. Södergren, P. G. Andersson and P.-O. Norrby, J. Am. Chem. Soc., 2000, 122, 8013–8020 Search PubMed.
  49. D. Leca, K. Song, M. Amatore, L. Fensterbank, E. Lacôte and M. Malacria, Chem.–Eur. J., 2004, 10, 906–916 CrossRef CAS PubMed.
  50. D. L. Orsi, B. J. Easley, A. M. Lick and R. A. Altman, Org. Lett., 2017, 19, 1570–1573 CrossRef CAS.
  51. (a) CCDC 2450631: Experimental Crystal Structure Determination, 2025,  DOI:10.5517/ccdc.csd.cc2n82mn; (b) CCDC 2431747: Experimental Crystal Structure Determination, 2025,  DOI:10.5517/ccdc.csd.cc2mmfg5; (c) CCDC 2451688: Experimental Crystal Structure Determination, 2025,  DOI:10.5517/ccdc.csd.cc2n95qw; (d) CCDC 2450394: Experimental Crystal Structure Determination, 2025,  DOI:10.5517/ccdc.csd.cc2n7tzq; (e) CCDC 2450395: Experimental Crystal Structure Determination, 2025,  DOI:10.5517/ccdc.csd.cc2n7v0s.

Footnote

These authors contributed equally to this work.

This journal is © The Royal Society of Chemistry 2026
Click here to see how this site uses Cookies. View our privacy policy here.